ClinConnect ClinConnect Logo
Search / Trial NCT05723081

Oklahoma Study of Native American Pain Risk III: Stress and Resilience

Launched by UNIVERSITY OF OKLAHOMA · Feb 1, 2023

Trial Information

Current as of August 26, 2025

Recruiting

Keywords

Structural Racism And Discrimination Stress Reactivity Quantitative Sensory Testing

ClinConnect Summary

The Oklahoma Study of Native American Pain Risk III is a research project aimed at understanding how certain social factors, specifically discrimination and structural racism, affect chronic pain in Native American adults. Researchers want to find out how these negative experiences influence the way pain develops and what factors might help protect against these effects. They’re especially interested in the relationship between stress and resilience—essentially, how some people cope better than others in tough situations.

To participate in this study, you need to identify as Native American or American Indian and be between the ages of 65 and 74. However, if you have certain medical conditions, like ongoing pain or serious mental health issues, or if you are using specific medications that could affect the study, you may not be eligible. If you join, you can expect to share your experiences and possibly complete some assessments to help the researchers understand the links between discrimination, stress, and pain. This study is currently looking for participants, and your involvement could help improve understanding and treatment of pain in Native American communities.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Self-identify as Native American/American Indian
  • Exclusion Criteria:
  • \<18 years of age
  • Self-reported history of cardiovascular, neuroendocrine, musculoskeletal, or neurological disorders
  • Surrent chronic pain, defined as persistent, bothersome pain on more days than not for at least 3 months)
  • Self-reported current substance dependence
  • Sse of medication that could interfere with testing (e.g., recent use of analgesics, antidepressants, or anti-anxiety medications)
  • Inability to speak English
  • Current psychosis (assessed by Psychosis Screening Questionnaire)
  • Serious cognitive impairment (assessed by \<20 score on the Montreal Cognitive Assessment \[MoCA\])
  • Possible peripheral neuropathy (assessed by nerve conduction study)

About University Of Oklahoma

The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.

Locations

Tulsa, Oklahoma, United States

Tulsa, Oklahoma, United States

Patients applied

0 patients applied

Trial Officials

Jamie L Rhudy, PhD

Principal Investigator

University of Oklahoma

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials